Please assess the completion status of the following clinical trial:

Trial Title: Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being diagnosed with a spinal cord injury less than 12 weeks of etiology stable,~* level of injury C5 L2,~* AIS grade A to D.~* Female or male between 18 and 45 years.~* No pregnancy.~* No osteoporosis.~* Good oral health.~* Good glomerular filtration.~* No cons-indication to Zoledronic Acid.~* No drugs affecting bone metabolism~Exclusion Criteria:~* pregnancy.~* osteoporosis.~* cons-indication to Zoledronic Acid.~* drugs affecting bone metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (Type: ACTIVE_COMPARATOR): Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
- NACL (Type: PLACEBO_COMPARATOR): NACl 100 ml IV. 3 infusions. Administration 3 times over two years.

Based on this trial design, predict the completion outcome and termination type (if applicable).